With the CANOVA results in mind, would you continue using venetoclax in patients with multiple myeloma with t(11;14)?

TL;DR - I will still be using venetoclax for t(11;14) myeloma in the way that I have been doing so for some time, which is in combination with other active myeloma agents. I prefer venetoclax 400 mg daily, in combination with either carfilzomib 56 mg/m2 weekly or daratumumab SQ.

Now the long version:...